<p>中央太平洋银行信托部门在最近向美国证券交易委员会提交的文件中表示，在第三季度将其在 Insulet Corporation（NASDAQ:PODD - 免费报告）中的股份减少了 99.8%。该基金在季度内出售了 291,000 股后，持有 480 股该医疗器械供应商的股票。中央太平洋银行信托部门在 Insulet 的持股在最近一个季度末价值为 148,000 美元。</p>
<ul>
<li>2025 年表现优于市场的 3 只医疗科技股票</li>
</ul>
<p>其他一些机构投资者最近也买卖了 PODD 的股票。Kozak &amp; Associates Inc.在第二季度购买了 Insulet 的新股份，价值约为 32,000 美元。Golden State Wealth Management LLC 在第二季度将其在 Insulet 的股份增加了 202.9%。Golden State Wealth Management LLC 现在拥有 103 股该医疗器械供应商的股票，价值 32,000 美元，此前在上个季度又购买了 69 股。托莱多信托公司（Trust Co. of Toledo NA OH）在第二季度购买了 Insulet 的新股份，价值约为 35,000 美元。Osterweis Capital Management Inc.在第二季度购买了 Insulet 的新股份，价值约为 51,000 美元。最后，NewEdge Advisors LLC 在第一季度将其在 Insulet 的持股增加了 44.8%。NewEdge Advisors LLC 现在拥有 207 股该医疗器械供应商的股票，价值 54,000 美元，此前在此期间又购买了 64 股。</p>
<h2>Insulet 股票上涨 0.3%</h2>
<p>Insulet 股票周四开盘价为 289.57 美元。该公司的债务与股本比率为 0.68，流动比率为 2.87，速动比率为 2.18。该股票的市值为 203.7 亿美元，市盈率为 83.93，PEG 比率为 2.03，贝塔值为 1.37。该公司的 50 日移动平均线为 317.47 美元，200 日移动平均线为 314.16 美元。Insulet Corporation 的 1 年最低价为 230.05 美元，1 年最高价为 354.88 美元。</p>
<ul>
<li>Insulet 在第一季度业绩超预期，成为标准普尔 500 指数的顶尖表现者</li>
</ul>
<p>Insulet（NASDAQ:PODD - 获取免费报告）最近在 11 月 6 日（星期四）发布了季度财报。该医疗器械供应商报告季度每股收益为 1.24 美元，超出市场共识预期的 1.13 美元，超出幅度为 0.11 美元。Insulet 的净利润率为 9.76%，股本回报率为 24.36%。该公司在季度内的收入为 5.217 亿美元，而分析师预期为 6.787 亿美元。去年同期，该公司每股收益为 1.08 美元。公司的季度收入较去年同期增长了 29.9%。整体来看，研究分析师预计 Insulet Corporation 在本财年将发布每股收益 3.92 美元。</p>
<h2>分析师评级调整</h2>
<p>几位股票分析师对 PODD 股票发表了评论。BTIG Research 在 11 月 21 日的研究报告中将 Insulet 的目标价从 370.00 美元上调至 380.00 美元，并给予该公司 “买入” 评级。Jefferies Financial Group 在 11 月 6 日的报告中将 Insulet 的目标价从 375.00 美元上调至 400.00 美元，并给予该股票 “买入” 评级。Evercore ISI 在周二的研究报告中开始覆盖 Insulet 股票，给予 “跑赢大盘” 评级和 370.00 美元的目标价。Oppenheimer 在 9 月 8 日的研究报告中将 Insulet 的目标价从 324.00 美元上调至 365.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Rothschild &amp; Co Redburn 在 10 月 3 日的研究报告中将 Insulet 的目标价从 350.00 美元上调至 370.00 美元，并给予该股票 “买入” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，22 位给予 “买入” 评级，2 位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 380.05 美元。</p>
<ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
<p><strong>获取我们关于 Insulet 的最新研究报告</strong></p>
<h2>Insulet 公司简介</h2>
<p>（免费报告）</p>
<p>Insulet Corporation 开发、制造和销售用于胰岛素依赖型糖尿病患者的胰岛素输送系统。该公司的 Omnipod 平台包括 Omnipod 5 自动胰岛素输送系统（Omnipod 5），该系统在 Pod 中嵌入了专有的 AID 算法，能够与第三方连续血糖监测仪通过无线蓝牙通信获取血糖值；Omnipod DASH 具有蓝牙功能的 Pod，由类似智能手机的个人糖尿病管理器控制，配备彩色触摸屏用户界面；以及 Omnipod GO，一种独立的可穿戴胰岛素输送系统，提供 72 小时的持续快速作用胰岛素固定速率。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Insulet 更具吸引力</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>在上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>价值投资：在 2022 年这是一种好策略吗？提示：永远</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
<li>5 只值得考虑的高评级股息股票</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
<p><strong>想看看其他对 PODD 持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取 Insulet Corporation（NASDAQ:PODD - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Insulet 吗？</h2>
<p>在考虑 Insulet 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Insulet 并不在名单上。</p>
<p>虽然 Insulet 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PODD

<p>中央太平洋银行信托部门在第三季度将其在 Insulet Corporation 的持股减少了 99.8%，出售了 291,000 股，保留了 480 股，价值为 148,000 美元。尽管如此，Insulet 的股票表现依然强劲，分析师维持 “适度买入” 评级，普遍目标价为 380.05 美元。该公司报告的季度收入同比增长 29.9%</p>

<p>Central Pacific Bank Trust Division lowered its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 99.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 480 shares of the medical instruments supplier's stock after selling 291,000 shares during the quarter. Central Pacific Bank Trust Division's holdings in Insulet were worth $148,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>中央太平洋银行信托部门在最近向美国证券交易委员会提交的文件中表示，在第三季度将其在 Insulet Corporation（NASDAQ:PODD - 免费报告）中的股份减少了 99.8%。该基金在季度内出售了 291,000 股后，持有 480 股该医疗器械供应商的股票。中央太平洋银行信托部门在 Insulet 的持股在最近一个季度末价值为 148,000 美元。</p>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年表现优于市场的 3 只医疗科技股票</li>
</ul>
</div><p>A number of other institutional investors also recently bought and sold shares of PODD. Kozak &amp; Associates Inc. bought a new stake in shares of Insulet in the 2nd quarter worth about $32,000. Golden State Wealth Management LLC lifted its stake in Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 69 shares during the last quarter. Trust Co. of Toledo NA OH purchased a new position in shares of Insulet during the second quarter valued at approximately $35,000. Osterweis Capital Management Inc. bought a new position in shares of Insulet during the second quarter valued at approximately $51,000. Finally, NewEdge Advisors LLC raised its holdings in shares of Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier's stock worth $54,000 after buying an additional 64 shares during the period.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也买卖了 PODD 的股票。Kozak &amp; Associates Inc.在第二季度购买了 Insulet 的新股份，价值约为 32,000 美元。Golden State Wealth Management LLC 在第二季度将其在 Insulet 的股份增加了 202.9%。Golden State Wealth Management LLC 现在拥有 103 股该医疗器械供应商的股票，价值 32,000 美元，此前在上个季度又购买了 69 股。托莱多信托公司（Trust Co. of Toledo NA OH）在第二季度购买了 Insulet 的新股份，价值约为 35,000 美元。Osterweis Capital Management Inc.在第二季度购买了 Insulet 的新股份，价值约为 51,000 美元。最后，NewEdge Advisors LLC 在第一季度将其在 Insulet 的持股增加了 44.8%。NewEdge Advisors LLC 现在拥有 207 股该医疗器械供应商的股票，价值 54,000 美元，此前在此期间又购买了 64 股。</p>
</div><h2>Insulet Stock Up 0.3%</h2>
<div class="lb-trans"><h2>Insulet 股票上涨 0.3%</h2>
</div><p>Shares of Insulet stock opened at $289.57 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. The stock has a market cap of $20.37 billion, a price-to-earnings ratio of 83.93, a PEG ratio of 2.03 and a beta of 1.37. The firm's 50-day moving average is $317.47 and its two-hundred day moving average is $314.16. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88.</p>
<div class="lb-trans"><p>Insulet 股票周四开盘价为 289.57 美元。该公司的债务与股本比率为 0.68，流动比率为 2.87，速动比率为 2.18。该股票的市值为 203.7 亿美元，市盈率为 83.93，PEG 比率为 2.03，贝塔值为 1.37。该公司的 50 日移动平均线为 317.47 美元，200 日移动平均线为 314.16 美元。Insulet Corporation 的 1 年最低价为 230.05 美元，1 年最高价为 354.88 美元。</p>
</div><ul>
<li>Insulet Surges on Q1 Beat, Emerges as a Top S&amp;P 500 Performer</li>
</ul>
<div class="lb-trans"><ul>
<li>Insulet 在第一季度业绩超预期，成为标准普尔 500 指数的顶尖表现者</li>
</ul>
</div><p>Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The business had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. During the same quarter in the previous year, the business posted $1.08 EPS. The company's quarterly revenue was up 29.9% compared to the same quarter last year. As a group, research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Insulet（NASDAQ:PODD - 获取免费报告）最近在 11 月 6 日（星期四）发布了季度财报。该医疗器械供应商报告季度每股收益为 1.24 美元，超出市场共识预期的 1.13 美元，超出幅度为 0.11 美元。Insulet 的净利润率为 9.76%，股本回报率为 24.36%。该公司在季度内的收入为 5.217 亿美元，而分析师预期为 6.787 亿美元。去年同期，该公司每股收益为 1.08 美元。公司的季度收入较去年同期增长了 29.9%。整体来看，研究分析师预计 Insulet Corporation 在本财年将发布每股收益 3.92 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several equities analysts have commented on PODD shares. BTIG Research upped their price objective on Insulet from $370.00 to $380.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, November 21st. Jefferies Financial Group upped their price target on shares of Insulet from $375.00 to $400.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, November 6th. Evercore ISI started coverage on shares of Insulet in a research note on Tuesday. They issued an &#34;outperform&#34; rating and a $370.00 price target on the stock. Oppenheimer boosted their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, September 8th. Finally, Rothschild &amp; Co Redburn raised their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $380.05.</p>
<div class="lb-trans"><p>几位股票分析师对 PODD 股票发表了评论。BTIG Research 在 11 月 21 日的研究报告中将 Insulet 的目标价从 370.00 美元上调至 380.00 美元，并给予该公司 “买入” 评级。Jefferies Financial Group 在 11 月 6 日的报告中将 Insulet 的目标价从 375.00 美元上调至 400.00 美元，并给予该股票 “买入” 评级。Evercore ISI 在周二的研究报告中开始覆盖 Insulet 股票，给予 “跑赢大盘” 评级和 370.00 美元的目标价。Oppenheimer 在 9 月 8 日的研究报告中将 Insulet 的目标价从 324.00 美元上调至 365.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Rothschild &amp; Co Redburn 在 10 月 3 日的研究报告中将 Insulet 的目标价从 350.00 美元上调至 370.00 美元，并给予该股票 “买入” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，22 位给予 “买入” 评级，2 位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 380.05 美元。</p>
</div><ul>
<li>Are These 5 Undervalued Stocks Ready to Break Out?</li>
</ul>
<div class="lb-trans"><ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
</div><p><strong>Get Our Latest Research Report on Insulet</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Insulet 的最新研究报告</strong></p>
</div><h2>Insulet Profile</h2>
<div class="lb-trans"><h2>Insulet 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.</p>
<div class="lb-trans"><p>Insulet Corporation 开发、制造和销售用于胰岛素依赖型糖尿病患者的胰岛素输送系统。该公司的 Omnipod 平台包括 Omnipod 5 自动胰岛素输送系统（Omnipod 5），该系统在 Pod 中嵌入了专有的 AID 算法，能够与第三方连续血糖监测仪通过无线蓝牙通信获取血糖值；Omnipod DASH 具有蓝牙功能的 Pod，由类似智能手机的个人糖尿病管理器控制，配备彩色触摸屏用户界面；以及 Omnipod GO，一种独立的可穿戴胰岛素输送系统，提供 72 小时的持续快速作用胰岛素固定速率。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Insulet</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Insulet 更具吸引力</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>在上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>价值投资：在 2022 年这是一种好策略吗？提示：永远</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
<li>5 只值得考虑的高评级股息股票</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PODD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 PODD 持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取 Insulet Corporation（NASDAQ:PODD - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PODD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Insulet Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Insulet 吗？</h2>
</div><p>Before you consider Insulet, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Insulet 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Insulet 并不在名单上。</p>
</div><p>While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Insulet 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

中央太平洋银行信托部门减少了其在 Insulet Corporation $PODD 的股票持有量